JP2017537621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537621A5 JP2017537621A5 JP2017529013A JP2017529013A JP2017537621A5 JP 2017537621 A5 JP2017537621 A5 JP 2017537621A5 JP 2017529013 A JP2017529013 A JP 2017529013A JP 2017529013 A JP2017529013 A JP 2017529013A JP 2017537621 A5 JP2017537621 A5 JP 2017537621A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- recombinant nucleic
- antibody
- chain polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 43
- 238000000034 method Methods 0.000 claims 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 241000701022 Cytomegalovirus Species 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 235000005772 leucine Nutrition 0.000 claims 1
- 150000002614 leucines Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022111396A JP2022160435A (ja) | 2014-12-01 | 2022-07-11 | Ｄｎａ抗体構築物及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086157P | 2014-12-01 | 2014-12-01 | |
| US62/086,157 | 2014-12-01 | ||
| US201562213166P | 2015-09-02 | 2015-09-02 | |
| US62/213,166 | 2015-09-02 | ||
| PCT/US2015/063174 WO2016089862A1 (en) | 2014-12-01 | 2015-12-01 | Dna antibody constructs and method of using same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201725A Division JP2021052776A (ja) | 2014-12-01 | 2020-12-04 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2022111396A Division JP2022160435A (ja) | 2014-12-01 | 2022-07-11 | Ｄｎａ抗体構築物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537621A JP2017537621A (ja) | 2017-12-21 |
| JP2017537621A5 true JP2017537621A5 (enExample) | 2019-01-17 |
| JP7268958B2 JP7268958B2 (ja) | 2023-05-08 |
Family
ID=56092325
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529013A Active JP7268958B2 (ja) | 2014-12-01 | 2015-12-01 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2020201725A Pending JP2021052776A (ja) | 2014-12-01 | 2020-12-04 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2022111396A Pending JP2022160435A (ja) | 2014-12-01 | 2022-07-11 | Ｄｎａ抗体構築物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201725A Pending JP2021052776A (ja) | 2014-12-01 | 2020-12-04 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2022111396A Pending JP2022160435A (ja) | 2014-12-01 | 2022-07-11 | Ｄｎａ抗体構築物及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11278619B2 (enExample) |
| EP (1) | EP3226892A4 (enExample) |
| JP (3) | JP7268958B2 (enExample) |
| KR (1) | KR20170085131A (enExample) |
| CN (2) | CN114010802A (enExample) |
| AU (3) | AU2015355126B9 (enExample) |
| BR (1) | BR112017011556A2 (enExample) |
| CA (1) | CA2969214A1 (enExample) |
| MX (2) | MX2017007187A (enExample) |
| WO (1) | WO2016089862A1 (enExample) |
| ZA (1) | ZA201703710B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015089492A2 (en) * | 2013-12-13 | 2015-06-18 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| BR112017011556A2 (en) * | 2014-12-01 | 2018-03-06 | The Trustees Of The University Of Pennsylvania | methods for generating a synthetic antibody, preventing or treating a disease, treating a subject of pathogen infection and a subject with cancer, product, nucleic acid molecule, and composition. |
| EP3452504A4 (en) * | 2016-05-05 | 2020-07-29 | The Trustees of The University of Pennsylvania | MONOCLONAL DNA ANTIBODIES TARGETING INFLUENZA VIRUS |
| EP3515482A4 (en) * | 2016-09-19 | 2020-09-30 | The Wistar Institute Of Anatomy And Biology | ASSOCIATION OF NEW ZIKA VIRUS VACCINES AND ANTI-DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST ZIKA VIRUS |
| KR20210117359A (ko) * | 2016-11-07 | 2021-09-28 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 라임병에 사용하기 위한 dna 항체 작제물 |
| CN116392609A (zh) * | 2017-03-23 | 2023-07-07 | Dnarx公司 | 用于体内核酸表达的系统和方法 |
| BR112019020235A2 (pt) | 2017-03-27 | 2020-04-22 | The Wistar Institute Of Anatomy And Biology | molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo. |
| CA3063051A1 (en) * | 2017-05-10 | 2018-11-15 | The Wistar Institute Of Anatomy And Biology | Optimized nucleic acid antibody constructs |
| AU2018280871B2 (en) | 2017-06-08 | 2024-09-26 | Black Belt Therapeutics Ltd | CD38 modulating antibody |
| EP3668543A1 (en) | 2017-08-16 | 2020-06-24 | Black Belt Therapeutics Limited | Cd38 antibody |
| WO2019034752A1 (en) | 2017-08-16 | 2019-02-21 | Tusk Therapeutics Ltd | Cd38 modulating antibody |
| US12162925B2 (en) * | 2017-09-15 | 2024-12-10 | The Wistar Institute Of Anatomy And Biology | DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein |
| US12195536B2 (en) | 2017-10-06 | 2025-01-14 | The Wistar Institute Of Anatomy And Biology | DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer |
| US12110342B2 (en) | 2018-01-31 | 2024-10-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use |
| CN111253493B (zh) * | 2020-03-05 | 2021-03-23 | 武汉科技大学 | 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用 |
| PH12022553102A1 (en) | 2020-05-14 | 2023-11-20 | Inovio Pharmaceuticals Inc | Vaccines for recurrent respiratory papillomatosis and methods of using the same |
| CN118725096B (zh) * | 2024-08-08 | 2025-02-07 | 兰州大学 | 一种ns1蛋白单克隆抗体及其应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5914109A (en) * | 1990-06-15 | 1999-06-22 | New York University | Heterohybridomas producing human monoclonal antibodies to HIV-1 |
| WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| WO1994016737A1 (en) | 1993-01-26 | 1994-08-04 | Weiner David B | Compositions and methods for delivery of genetic material |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6025158A (en) * | 1997-02-21 | 2000-02-15 | Genentech, Inc. | Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies |
| IL132103A0 (en) | 1997-04-03 | 2001-03-19 | Eletrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US7276488B2 (en) * | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
| DE69826124T3 (de) | 1997-06-30 | 2007-10-11 | Institut Gustave Roussy | Verabreichung der nukleinsäure in den quergestreiften muskel |
| EP2428250A1 (en) | 1998-07-13 | 2012-03-14 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US20030039635A1 (en) | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030073613A1 (en) * | 2000-03-22 | 2003-04-17 | Mary Gerritsen | Angiogenisis associated proteins, and nucleic acids encoding the same |
| US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| CA2504593C (en) | 2002-11-04 | 2016-08-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| DK1628749T3 (da) | 2003-05-30 | 2019-09-16 | Vgxi Inc | Anordninger og fremgangsmåder til biomateriel produktion |
| CN1480215A (zh) | 2003-07-07 | 2004-03-10 | 叶新新 | Sars病毒抗原抗体复合疫苗及实验动物模型与方法 |
| EP2428522A1 (en) | 2004-05-28 | 2012-03-14 | Agensys, Inc. | Antibodies that bind to PSCA proteins for diagnosis of cancer |
| BRPI0520902B1 (pt) | 2004-05-28 | 2021-11-30 | Agensys, Inc | Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca |
| EP1765846A4 (en) | 2004-07-13 | 2010-02-17 | Cell Genesys Inc | AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION |
| HRP20141111T1 (hr) | 2004-07-22 | 2015-01-02 | Genentech, Inc. | Sastav her2-protutijela |
| CN101160324B (zh) | 2005-02-18 | 2013-04-24 | 米德列斯公司 | 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体 |
| US20060216722A1 (en) | 2005-03-25 | 2006-09-28 | Christer Betsholtz | Glomerular expression profiling |
| EP2468881A3 (en) | 2005-07-21 | 2012-08-15 | Abbott Laboratories | Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| CA2598966A1 (en) | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
| JP2009171880A (ja) | 2008-01-23 | 2009-08-06 | Yokohama City Univ | アルツハイマー病における次世代遺伝子治療法・免疫治療法の開発 |
| CN101970496B (zh) | 2008-03-14 | 2014-04-16 | 特朗斯吉有限公司 | 针对csf-1r的抗体 |
| ES2588738T3 (es) | 2008-04-04 | 2016-11-04 | The Trustees Of The University Of Pennsylvania | Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas |
| CN102272155B (zh) | 2008-10-13 | 2018-05-25 | 生物医学研究所 | 登革热病毒中和抗体及其用途 |
| SG177560A1 (en) | 2009-07-06 | 2012-03-29 | Hoffmann La Roche | Bi-specific digoxigenin binding antibodies |
| BR112012000588A2 (pt) | 2009-07-13 | 2020-08-11 | Bharat Biotech International Limited | composição, composição líquida, composição liofilizada e método para produzir um rotavirus atenuado |
| US20110045534A1 (en) | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
| CA2774636C (en) * | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| EP2591000B1 (en) | 2010-07-09 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| MX346784B (es) | 2010-11-12 | 2017-03-31 | Inovio Pharmaceuticals Inc | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. |
| EA033467B1 (ru) | 2011-01-31 | 2019-10-31 | Univ Pennsylvania | Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| US8865881B2 (en) | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| WO2013177533A1 (en) | 2012-05-25 | 2013-11-28 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| KR20230156146A (ko) | 2012-12-13 | 2023-11-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ｄｎａ 항체 작제물 및 그 이용 방법 |
| PL2931304T3 (pl) | 2012-12-13 | 2021-11-08 | The Trustees Of The University Of Pennsylvania | Szczepionka wt1 |
| WO2015089492A2 (en) | 2013-12-13 | 2015-06-18 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| US20140377269A1 (en) | 2012-12-19 | 2014-12-25 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| BR112017011556A2 (en) * | 2014-12-01 | 2018-03-06 | The Trustees Of The University Of Pennsylvania | methods for generating a synthetic antibody, preventing or treating a disease, treating a subject of pathogen infection and a subject with cancer, product, nucleic acid molecule, and composition. |
| HRP20230115T1 (hr) * | 2018-07-31 | 2023-06-09 | Heidelberg Pharma Research Gmbh | Humanizirana antitijela protiv psma |
-
2015
- 2015-12-01 BR BR112017011556-5A patent/BR112017011556A2/en not_active Application Discontinuation
- 2015-12-01 CN CN202110892131.5A patent/CN114010802A/zh active Pending
- 2015-12-01 KR KR1020177017224A patent/KR20170085131A/ko active Pending
- 2015-12-01 JP JP2017529013A patent/JP7268958B2/ja active Active
- 2015-12-01 WO PCT/US2015/063174 patent/WO2016089862A1/en not_active Ceased
- 2015-12-01 MX MX2017007187A patent/MX2017007187A/es unknown
- 2015-12-01 US US15/532,162 patent/US11278619B2/en active Active
- 2015-12-01 CN CN201580075039.2A patent/CN107427566B/zh active Active
- 2015-12-01 AU AU2015355126A patent/AU2015355126B9/en active Active
- 2015-12-01 CA CA2969214A patent/CA2969214A1/en active Pending
- 2015-12-01 EP EP15864627.3A patent/EP3226892A4/en not_active Withdrawn
-
2017
- 2017-05-30 ZA ZA201703710A patent/ZA201703710B/en unknown
- 2017-06-05 MX MX2023009421A patent/MX2023009421A/es unknown
-
2019
- 2019-04-08 AU AU2019202433A patent/AU2019202433A1/en not_active Abandoned
-
2020
- 2020-12-04 JP JP2020201725A patent/JP2021052776A/ja active Pending
-
2021
- 2021-03-12 AU AU2021201586A patent/AU2021201586A1/en not_active Abandoned
-
2022
- 2022-03-03 US US17/685,586 patent/US20230023093A1/en not_active Abandoned
- 2022-07-11 JP JP2022111396A patent/JP2022160435A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021087433A5 (enExample) | ||
| JP2016501535A5 (enExample) | ||
| US11578131B2 (en) | Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules | |
| US20220169751A1 (en) | Multimeric ox40 binding molecules and uses thereof | |
| US20210388098A1 (en) | Multimeric cd137/4-1bb binding molecules and uses thereof | |
| JP2020114213A (ja) | 二重特異性ｔ細胞活性化抗原結合分子 | |
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| JP2016053091A5 (enExample) | ||
| US20220098274A1 (en) | Engineered pd-1 variants | |
| HRP20150300T4 (hr) | Novi i snažni mhc-razred ii peptidi derivirani iz survivina i neurokana | |
| JP2019528683A (ja) | 多量体ｇｉｔｒ結合分子及びその使用 | |
| JP2021511053A (ja) | 標的サイレンシングタンパク質の細胞内送達 | |
| JP2020521478A5 (enExample) | ||
| JP2018512124A5 (enExample) | ||
| JP2021518168A (ja) | 拮抗的抗原結合タンパク質 | |
| JP2014534807A (ja) | クロスプレゼンテーションを行う樹状細胞を標的としたワクチボディ | |
| NZ760008A (en) | Uti fusion proteins | |
| JP2019505565A5 (enExample) | ||
| EP3253790A2 (en) | Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection | |
| RU2020115161A (ru) | Днк моноклональных антител против ctla-4 для лечения и профилактики рака | |
| Dashtiahangar et al. | Anti-cancer immunotoxins, challenges, and approaches | |
| JPWO2020071554A5 (enExample) | ||
| CA3124688A1 (en) | Truncated multivalent multimers | |
| JP2022540089A5 (enExample) | ||
| US20220235135A1 (en) | Activating anti-gal9 binding molecules |